Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemizon expands research collaboration with Takeda
Tony Piscopio, chairman and CEO of Optomagic, said: “We are pleased that Takeda has decided to further expand its partnership with Chemizon. With our recently announced strategic partnership
Tony Piscopio, chairman and CEO of Optomagic, said: “We are pleased that Takeda has decided to further expand its partnership with Chemizon. With our recently announced strategic partnership
This approval is claimed to be the first for Humira in Japan, where Abbott co-developed and will co-market Humira with Eisai. Humira is expected to become available to
Under the terms of the agreement, Codon will receive clinical milestone payments and royalties on net sales that may result from Merrimack’s development and commercialization of any protein
Ofloxacin ophthalmic solution is an anti-infective used to treat infections caused by bacteria in conjunctivitis and corneal ulcers. Arthur Przybyl, Akorn’s president and CEO, said: “This product will
The company anticipates that this investment will create more than 100 new jobs in Massachusetts. The investment will support the construction of a center of excellence in discovery,
The results showed that 73% of patients who began the study on FTY720 (fingolimod) 5mg remained free from relapses after three years, and 68% of those who began
All patients vaccinated with CDX-110 in the Phase IIa ACT II extension study showed a tumor-specific immune response, a significant improvement over previous vaccines and over CDX-110 alone.
These results suggest that inhibiting the Hedgehog pathway with IPI-926, the company’s novel, potent Hedgehog pathway antagonist following chemotherapy delays tumor recurrence in small cell lung cancer (SCLC).
CV Therapeutics has received $175 million on closing of the transaction and could receive a potential future milestone payment of $10 million. CV Therapeutics retains rights to the
In the current study, radiation of glioma xenografts led to induction of hypoxia-inducible factor (HIF)-1 as measured in vivo by HIF-1 dependent PET imaging. PX-478 inhibited this induction